Pharmaceutical companies have shown little interest in dialing back recommended dosages. Once they set the price for a drug, the more sales, the more profit. One study that examined 29 expensive ...

Patients and researchers point to evidence that many cancer drug dosages are excessive, and that reducing the amount and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced ...

Aug 4 (Reuters) – Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda. The U.S.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Please provide your email address to receive an email when new articles are posted on . The FDA approved belzutifan with pembrolizumab as an adjuvant therapy for adults with renal cell carcinoma. The ...

Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for a planned phase 3 study, completing the trio of contributors needed to run the colorectal cancer trial. California-based ...

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro has surpassed Merck & Co.’s cancer therapy Keytruda as the world’s best-selling medication. Mounjaro generated $8.7 billion for Lilly in the first ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

Merck (MRK) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's ...